Last updated: August 2026
Home › Blog › Latest Research into B3 Nicotinamide
⚠️ Educational content only. B3 Nicotinamide is a food supplement — not a medicine. The 6 authorised EU/UK health claims for niacin are clearly identified throughout. All other research content is educational context only — not health claims for any product. Always consult your GP before starting any supplement.
Vitamin B3 has been studied for decades — but the research picture around nicotinamide specifically has accelerated significantly in recent years, particularly in the context of NAD+ biology, skin health and the expanding interest in cellular ageing research. This guide covers what the published literature currently says about nicotinamide (niacinamide) — the flush-free amide form of vitamin B3 — and how it differs from its close relative, nicotinic acid (the flushing form).
Everything here is educational context drawn from published research — not health claims for any product. The 6 authorised EU/UK health claims for niacin are identified clearly where they apply. All other content is research background only. Food supplement — not a medicine.
What Is B3 Nicotinamide — And How Does It Differ from Niacin?
Nicotinamide (also called niacinamide, pyridine-3-carboxamide) is the amide form of vitamin B3. It is one of the two main supplemental forms of niacin — the other being nicotinic acid. Both are forms of vitamin B3 and both carry the same 6 authorised EU/UK health claims. The critical structural difference is a single chemical group: nicotinamide has an amide group (–CONH₂) where nicotinic acid has a carboxylic acid group (–COOH).
That single structural difference has significant practical consequences — nicotinamide does not activate GPR109A prostaglandin receptors in the skin, which means it does not cause the niacin flush. This makes it the preferred choice for the majority of users who want vitamin B3 without the skin redness and tingling that nicotinic acid causes.
| Property | Nicotinamide ← Non-Flush ✅ | Nicotinic Acid — Flush Form |
|---|---|---|
| Also known as | Niacinamide · flush-free B3 | Niacin · flushing B3 |
| Niacin flush? | ✅ None | 🔴 Yes — skin redness/tingling |
| NAD pathway | Salvage pathway | Preiss-Handler pathway |
| Authorised claims | Same 6 authorised claims | Same 6 authorised claims |
| Skin research | Extensive published research | Less skin-specific research |
THE 6 AUTHORISED EU/UK HEALTH CLAIMS FOR NIACIN (VITAMIN B3)
These are the only legally authorised health claims for vitamin B3 under retained Regulation 1924/2006. They apply to all forms of niacin including nicotinamide. Exact wording must be used.
⚡ Energy Metabolism
"Niacin contributes to normal energy-yielding metabolism"
🧠 Nervous System
"Niacin contributes to normal functioning of the nervous system"
🧘 Psychological Function
"Niacin contributes to normal psychological function"
💪 Tiredness & Fatigue
"Niacin contributes to the reduction of tiredness and fatigue"
🌿 Skin & Mucous Membranes
"Niacin contributes to the maintenance of normal skin and mucous membranes"
🛡️ Mucous Membranes
"Niacin contributes to the maintenance of normal mucous membranes"
Authorised under retained Regulation EC No 1924/2006. These are the only claims legally usable for vitamin B3 supplements in the UK.
Nicotinamide as a NAD+ Precursor — The Salvage Pathway
Educational research context only — not health claims. Food supplement — not a medicine.
One of the most active areas of published research into nicotinamide centres on its role as a NAD+ precursor. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell and essential for over 400 enzymatic reactions, particularly in energy production, DNA repair and sirtuin activation. NAD+ levels are known to decline with age — a well-documented biological fact that has driven significant research interest in NAD+ precursor supplementation.
Nicotinamide enters the NAD+ synthesis pathway via the salvage pathway — one of three main routes the body uses to produce NAD+. The salvage pathway converts nicotinamide → nicotinamide mononucleotide (NMN) via the enzyme NAMPT (nicotinamide phosphoribosyltransferase), then NMN → NAD+. This is considered a highly efficient conversion route. The landmark Christen et al. (2025) study in Nature Metabolism examined head-to-head comparisons between NMN, NR and niacin — finding NMN to be the most efficient at sustainably doubling circulating NAD+, while confirming all three compounds raise NAD+ via related but distinct pathways.
The Salvage Pathway — How Nicotinamide Becomes NAD+
Nicotinamide → (NAMPT enzyme) → NMN → (NMNAT enzyme) → NAD+. This two-step conversion is the primary intracellular route for nicotinamide to enter the NAD+ pool. NAMPT is considered the rate-limiting enzyme in this pathway — its activity declines with age, which is one reason NAD+ levels fall in older tissues. Educational context only — not a product claim.
Nicotinamide vs NMN vs NR — Where Each Enters the NAD+ Pathway
Nicotinamide is converted to NMN first, then to NAD+. NR (nicotinamide riboside) is also converted to NMN first, then to NAD+. NMN enters the pathway one step later — directly as the immediate NAD+ precursor. This is why NMN and NR are typically studied at much lower doses (250–500mg) than nicotinamide supplementation doses — they enter at a more downstream point. Educational context only — not health claims.
NAMPT — The Rate-Limiting Enzyme
Published research has identified NAMPT (nicotinamide phosphoribosyltransferase) as the rate-limiting enzyme in the nicotinamide salvage pathway. NAMPT activity is reduced in aged tissues and under conditions of metabolic stress. This means the efficiency with which nicotinamide converts to NAD+ may vary by individual and age — a factor worth noting in the context of high-dose nicotinamide supplementation. Educational context only.
📚 Key Research — NAD+ Pathway · Educational Context Only
Christen et al. (2025) — Head-to-head NMN vs NR vs Niacin · Nature Metabolism · doi:10.1038/s42255-025-01421-8 →
Verdin (2015) — NAD+ in ageing and metabolism · Science · PubMed 24270807 →
Revollo et al. (2004) — NAMPT and the NAD+ biosynthetic pathway · Journal of Biological Chemistry · PubMed 15358785
Nicotinamide and Skin Health — What the Research Shows
Educational research context only. The authorised claim for skin is: "Niacin contributes to the maintenance of normal skin and mucous membranes." All other content below is research context — not a product claim.
Nicotinamide has one of the most extensive published research bodies of any vitamin B3 form in relation to skin biology. It has been studied in the context of DNA repair in UV-damaged skin cells, sebum regulation, and barrier function. Dermatologists have been recommending niacinamide as a topical ingredient for years — but the published literature on oral nicotinamide is also substantial.
UV-Induced DNA Damage — Published Research Context
Published research has examined nicotinamide's role in DNA repair pathways following UV radiation exposure. NAD+ is required by PARP enzymes (poly ADP-ribose polymerases) which are involved in detecting and repairing DNA damage. Nicotinamide, as a NAD+ precursor, has been studied in this context. Researchers including Drs Damian and Halliday at the University of Sydney published research examining oral nicotinamide in this area. Educational context only — not a product claim. Food supplement — not a medicine.
Chen et al. (2015) — Phase III Published Trial · New England Journal of Medicine
A randomised controlled trial (Chen et al., 2015, NEJM · PubMed 26488693) examined oral nicotinamide 500mg twice daily vs placebo in a specific high-risk patient group over 12 months. Published findings from this trial are a matter of public record and freely available via PubMed. We are not stating that this trial demonstrates benefit from our product — it is cited for educational reference to illustrate the published research context only. This research was conducted in a specific clinical setting — it is not a general nutrition study. Food supplement — not a medicine. Always consult your GP.
Sebum Regulation — Topical and Oral Research
Niacinamide has been studied extensively in topical form for sebum regulation and skin barrier function. Published research describes inhibitory effects on sebocyte lipid synthesis. The oral form has been studied less specifically in this context but the systemic availability of nicotinamide as a NAD+ precursor across skin tissues is well established in published biology. Educational context only — not a health claim.
📚 Key Research — Skin · Educational Context Only
Chen et al. (2015) — Oral nicotinamide 500mg twice daily · New England Journal of Medicine · PubMed 26488693 →
Damian (2014) — Nicotinamide and DNA repair in UV-damaged skin · Experimental Dermatology · PubMed 25186539
Energy Metabolism and the Nervous System — The Authorised Claims in Context
The authorised claims here are: "Niacin contributes to normal energy-yielding metabolism" and "Niacin contributes to normal functioning of the nervous system." Research context below explains the biological basis for these claims.
The authorised claims for energy metabolism and nervous system function reflect well-established nutritional science. NAD+ and NADH are essential coenzymes in the mitochondrial electron transport chain — the process by which cells convert nutrients into ATP (cellular energy). Without sufficient niacin, this process is compromised. Published nutritional biochemistry establishes niacin as an essential vitamin for energy metabolism — not just a supplemental add-on.
⚡ Energy — NAD+/NADH in Mitochondria
NAD+ and its reduced form NADH are the primary electron carriers in the citric acid cycle and electron transport chain. Every molecule of glucose that the cell converts to ATP passes through these NAD+-dependent reactions. The authorised claim reflects this fundamental nutritional science. Educational context.
🧠 Nervous System — Myelin and Neuronal Function
Niacin deficiency (pellagra) produces well-documented neurological symptoms — published medicine has established niacin as essential for neuronal function. Published research into NAD+ and neuronal energy metabolism continues to expand. The authorised claim reflects established nutritional biochemistry. Educational context.
THE FLUSH MECHANISM — WHY NICOTINAMIDE DOESN'T CAUSE IT
The niacin flush is one of the most misunderstood aspects of vitamin B3 supplementation. It is not an allergic reaction — it is a specific pharmacological effect of nicotinic acid only. Understanding why nicotinamide doesn't cause it requires a brief look at the mechanism.
Step 1 — GPR109A Receptor Activation
Nicotinic acid binds to GPR109A (also called HM74A or niacin receptor 1) — a G protein-coupled receptor expressed on Langerhans cells in the skin and on adipocytes. Nicotinamide does not bind this receptor with any meaningful affinity — the amide group prevents it. This is the fundamental molecular reason there is no flush with nicotinamide.
Step 2 — Prostaglandin D2 and E2 Release
GPR109A activation by nicotinic acid triggers the release of prostaglandin D2 and E2 from Langerhans cells. These prostaglandins cause capillary vasodilation in the skin — the small blood vessels under the skin dilate, increasing blood flow to the surface. This produces the visible redness, warmth and tingling. The flush begins 15–30 minutes post-dose and typically resolves within 30–60 minutes.
Step 3 — Why Some People Specifically Want the Flush
Some users specifically seek the nicotinic acid (flushing) form. The vasodilating properties of nicotinic acid are distinct from anything nicotinamide produces. Both forms carry the same 6 authorised EU/UK claims and both contribute to NAD+ synthesis — but via different mechanisms and with different physiological profiles. Educational context only — not a product claim for either form.
Recent Developments — What 2024 and 2025 Research Adds
Educational research context only — not health claims. Food supplement — not a medicine.
Christen et al. (2025) — NMN vs NR vs Niacin Head-to-Head · Nature Metabolism
The most significant recent publication covering the NAD+ precursor landscape. This head-to-head trial compared NMN, NR and niacin directly on their ability to raise circulating NAD+. Published findings showed NMN was most efficient at sustainably doubling NAD+, while confirming all three compounds raise NAD+ via related but distinct pathways. Nicotinamide (via salvage) and nicotinic acid (via Preiss-Handler) are positioned differently in this hierarchy. Educational context — not a product claim. doi:10.1038/s42255-025-01421-8
VA Cohort Study (2025) — Largest Real-World Oral Nicotinamide and Skin Dataset · JAMA Network
A large retrospective cohort study using Veterans Affairs electronic health record data from 33,822 patients (October 1999–December 2024, analyses conducted January–May 2025) examined oral nicotinamide supplementation and skin outcomes. This is the largest real-world dataset on oral nicotinamide and skin published to date — substantially extending the earlier Chen et al. NEJM 2015 RCT. Published findings are a matter of public record and are freely available via JAMA Network. We are not stating what this trial demonstrated as a benefit of any product — it is cited for educational research context only. Food supplement — not a medicine. Always consult your GP.
GeroMedicine Systematic Review (2025) — NAD+ Precursors in Ageing · RCTs 2020–2025
A systematic review published in 2025 covering randomised clinical trials between 2020 and 2025 on NAD+ precursors — including nicotinamide, NMN, NR and nicotinic acid — examining cardiac, vascular, cerebral, metabolic and skeletomuscular endpoints in middle-aged and older adults. The review represents the most comprehensive recent overview of clinical evidence across the NAD+ precursor class, including nicotinamide's position within it. Educational context only — not health claims. doi:10.70401/Geromedicine.2025.0008
Nicotinamide and Tau Protein — Published Neurological Research Context
A completed clinical trial (NCT03061474) examined whether high-dose oral nicotinamide could reduce phosphorylation of tau protein (p-tau231) — a biomarker studied in published neurological research. The mechanistic rationale was preclinical work in mouse models suggesting nicotinamide may act as a histone deacetylase (HDAC) inhibitor. This represents an emerging area of published research exploring nicotinamide's biochemistry beyond its established nutritional role. Educational research context only — not a health claim for any product and not a statement that this supplement is relevant to any neurological condition. Food supplement — not a medicine. Always consult your GP.
FASEB NAD+ Conference (2024) — Growing Heterogeneity and Dosing Research
The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling highlighted growing research interest in individual heterogeneity in NAD+ precursor response — specifically around dosing, timing and health condition-specific effects. This reflects a maturing field moving beyond establishing that NAD+ precursors raise NAD+ levels, towards understanding which precursor, at which dose, produces which effect in which individual. Nicotinamide's position in this conversation — as the most widely available and lowest-cost form — is increasingly studied. Educational context only.
Topical Niacinamide — Senomorphic Activity (2024) · Scientific Reports / Nature
A 2024 study in Scientific Reports (Nature Publishing Group) examined a combination of 6% niacinamide with multi-molecular weight hyaluronic acid and found it exhibited senomorphic activity — reducing markers of cellular ageing. Gene expression analysis revealed downregulation of 20 ageing-related genes. This is topical research — not directly applicable to oral supplementation — but adds to the growing body of published biology around niacinamide and cellular ageing pathways. Educational context only — not a health claim. Food supplement — not a medicine.
Growing Research into NAMPT and Ageing
Research has continued to characterise NAMPT (the rate-limiting enzyme in the nicotinamide salvage pathway) as a significant factor in age-related NAD+ decline. Studies in aged tissues have demonstrated reduced NAMPT expression — meaning the efficiency with which nicotinamide converts to NAD+ may be lower in older individuals. This is relevant to how nicotinamide supplementation is understood across different age groups. Educational context only.
⚠️ Safety — High-Dose Nicotinamide Context
500mg per capsule = 3,125% of the EU/UK NRV (16mg). This is a high-strength supplemental dose well above normal dietary intake. Published research has generally found nicotinamide to be well tolerated at doses used in clinical research — but high-dose use is not without considerations.
Food supplement — not a medicine. Not intended to diagnose, treat, cure or prevent any disease. Always consult your GP before starting high-dose supplementation.
OUR B3 RANGE — CHARGE PRODUCTS UK
Food supplements — not medicines. 161,000+ verified sales · 5 Star FSA · UK in-house since 2016
Related Products — NAD+ Precursor Range
📚 Published Literature Referenced
All references provided for educational context only — not health claims for any product. Food supplement — not a medicine.
Christen et al. (2025) — NMN vs NR vs Niacin head-to-head · Nature Metabolism
doi:10.1038/s42255-025-01421-8 →Chen et al. (2015) — Oral nicotinamide · New England Journal of Medicine
PubMed 26488693 →Verdin (2015) — NAD+ in ageing and metabolism · Science
PubMed 24270807 →Damian (2014) — Nicotinamide and DNA repair in UV-damaged skin · Experimental Dermatology
PubMed 25186539 →Revollo et al. (2004) — NAMPT and the NAD+ biosynthetic pathway · Journal of Biological Chemistry
PubMed 15358785
VA Cohort Study (2025) — Nicotinamide for skin cancer chemoprevention in 33,822 patients · JAMA Network
Analyses conducted January–May 2025 · largest real-world oral nicotinamide dataset published to date
GeroMedicine Systematic Review (2025) — Clinical evidence for NAD+ precursors in ageing · RCTs 2020–2025
doi:10.70401/Geromedicine.2025.0008 →NCT03061474 (2022) — Nicotinamide and tau phosphorylation in mild cognitive impairment and early Alzheimer's disease · Clinical trial completed
Search NCT03061474 on clinicaltrials.gov for full record
2024 FASEB Conference on NAD Metabolism and Signaling — precursor heterogeneity and dosing research
Conference proceedings — PubMed PMC12579426
Common Searches
b3 nicotinamide research uk · niacinamide research 2025 · nicotinamide nad+ precursor uk · b3 nicotinamide skin research · niacinamide salvage pathway uk · nicotinamide vs nicotinic acid research · b3 nicotinamide 500mg uk · flush free vitamin b3 research · nicotinamide dna repair research · niacinamide parp uk · nicotinamide nampt uk · b3 nicotinamide nad biology uk · latest b3 research uk · nicotinamide energy metabolism uk · niacinamide nervous system research · buy b3 nicotinamide uk · charge products b3 nicotinamide
